Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

By D. Cardinale, M. Sandri, A. Colombo, N. Colombo, M. Boeri, Giuseppina Lamantia, M. Civelli, F. Peccatori, G. Martinelli, C. Fiorentini and 1 more. Circulation, 2004

919 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/88e0d879276cc8c431f1e1a2dc41a4f237cb18df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Herrmann
2. Jose Luis Zamorano
3. J. Januzzi
4. D. Lenihan
5. P. Lancellotti
6. R. Russell
7. M. Volkova

In Oncology

1. J. Herrmann

Citations in the corpus

• Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, background): “In 1 study, the levation of troponin I soon after high-dose chemotherapy redicted the future development of LVEF depression (53), nd in another study, troponin I elevations identified atients at different risks of future cardiac events (54).”
• Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “In one study of 703 cancer patients, normal troponin I levels before and after anthracyclinebased ChT were associated with a low incidence of cardiac events (1%) during the >3-year follow-up, while patients with elevations in troponin I during the course of ChT had a greater incidence of major adver”
• Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. (2012, background): “In the last decade, a new approach, based on the use of cardiac biomarkers, in particular troponins, has emerged, and has proven to be a more sensitive and more specific tool for early, real-time identification, assessment and monitoring of anticancer druginduced cardiac injury [7, 8].”
• Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. (2010, background): “In cancer patients treated with high-dose chemotherapy, troponin I (TNI) is a well-established early marker of myocardial injury, with high diagnostic and high prognostic values.(16-18) Indeed, TNI increase has been shown to predict LVEF reduction and associated adverse cardiac events.”
• Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, neutral): “The largest of these studies was performed in 703 patients with cancer, in whomTnI was determined with each cycle of high-dose chemotherapy and 1 month after chemotherapy.(174) Patients were classified into three subgroups on the basis of the combined presence of any detectable TnI either within 72 ”
• Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients (2011, neutral): “Whereas Cardinale et al 11 detected elevated troponin in 33% of patients after high doses of anthracyclines, more recent studies report less frequent troponin elevation and no value in predicting the decrease in LVEF after anthracyclines.”